170 related articles for article (PubMed ID: 37647437)
1. Severe hemolytic exacerbations of Chinese PNH patients infected SARS-CoV-2 Omicron.
Yang H; Chai X; Gong Y; Zhang X; Wang L; Zhou X; Chen X; Xu J; Xu D; He G; Li J
Immun Inflamm Dis; 2023 Aug; 11(8):e966. PubMed ID: 37647437
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccination prevents a more severe course and treatment with complement inhibitors reduce worsening hemolysis during the Omicron pandemic in patients with PNH: a single-center study.
Wang L; Hu Q; Yang Y; Chen M; Yang C; Han B
Ann Med; 2023; 55(2):2274510. PubMed ID: 38163328
[TBL] [Abstract][Full Text] [Related]
3. Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria.
Kamura Y; Sakamoto T; Yokoyama Y; Nishikii H; Sakata-Yanagimoto M; Chiba S; Obara N
Int J Hematol; 2022 Jul; 116(1):55-59. PubMed ID: 35668275
[TBL] [Abstract][Full Text] [Related]
4. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
Risitano AM; Perna F; Selleri C
Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
[TBL] [Abstract][Full Text] [Related]
5. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
Risitano AM
Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
[TBL] [Abstract][Full Text] [Related]
6. Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature.
Fattizzo B; Pasquale R; Bellani V; Barcellini W; Kulasekararaj AG
Front Immunol; 2021; 12():791429. PubMed ID: 34899761
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea.
Kim JS; Jang JH; Jo DY; Ahn SY; Yoon SS; Lee JH; Kim SH; Choi CW; Shin HJ; Kim MK; Lee JH; Mun YC; Kong JH; Hyun B; Nam H; Kim E; Kwak MJ; Won YK; Lee JW
J Korean Med Sci; 2023 Oct; 38(41):e328. PubMed ID: 37873628
[TBL] [Abstract][Full Text] [Related]
8. Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Höchsmann B; de Fontbrune FS; Lee JW; Kulagin AD; Hillmen P; Wilson A; Marantz JL; Schrezenmeier H
Eur J Haematol; 2022 Sep; 109(3):197-204. PubMed ID: 35390189
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 Presented with Deep Vein Thrombosis in a Patient with Paroxysmal Nocturnal Haemoglobinuria.
Pravdic Z; Mitrovic M; Bogdanovic A; Virijevic M; Sabljic N; Pantic N; Vukovic NS
Hamostaseologie; 2021 Oct; 41(5):397-399. PubMed ID: 34544179
[TBL] [Abstract][Full Text] [Related]
10. [Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria].
Ishiyama K; Usuki K; Ikezoe T; Gotoh A; Myren KJ; Tomazos I; Shimono A; Ninomiya H; Sakurai M; Nakao S; Nishimura JI
Rinsho Ketsueki; 2023; 64(1):9-17. PubMed ID: 36775313
[TBL] [Abstract][Full Text] [Related]
11. Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress.
Peffault de Latour R; Hosokawa K; Risitano AM
Semin Hematol; 2022 Jan; 59(1):38-46. PubMed ID: 35491057
[TBL] [Abstract][Full Text] [Related]
12. Hemosiderin induced acute kidney injury requiring hemodialysis in patients with paroxysmal nocturnal hemoglobinuria: A case report.
Choi H; Yim H; Lee MJ
Medicine (Baltimore); 2023 Oct; 102(40):e35412. PubMed ID: 37800776
[TBL] [Abstract][Full Text] [Related]
13. Breakthrough Hemolysis Associated With COVID-19 Vaccination and Active COVID-19 Infection in a Patient With Paroxysmal Nocturnal Hemoglobinuria Maintained on Pegcetacoplan: A Case Report.
Boshkos MC; Fives KR; Phrathep DD; Healey KD; Patel M
Cureus; 2023 Mar; 15(3):e36240. PubMed ID: 37065335
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Valentine ME; Khursigara G; Ozawa K; Omine M
Int J Hematol; 2011 Jan; 93(1):36-46. PubMed ID: 21222185
[TBL] [Abstract][Full Text] [Related]
15. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
Notaro R; Sica M
Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network.
Füreder W; Sperr WR; Heibl S; Zebisch A; Pfeilstöcker M; Stefanzl G; Jäger E; Greiner G; Schwarzinger I; Kundi M; Keil F; Hoermann G; Bettelheim P; Valent P
Ann Hematol; 2020 Oct; 99(10):2303-2313. PubMed ID: 32856141
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of 512 eculizumab-naive paroxysmal nocturnal hemoglobinuria patients in China: a single-center observational study.
Du Y; Yang Y; Yang C; Chen M; Han B
Hematology; 2022 Dec; 27(1):113-121. PubMed ID: 35068377
[TBL] [Abstract][Full Text] [Related]
18. Erythopoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria.
Hill A; Richards SJ; Rother RP; Hillmen P
Haematologica; 2007 Mar; 92(3):e31-3. PubMed ID: 17405753
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]